Amicus Therapeutics (FOLD) Research & Development (2016 - 2025)
Amicus Therapeutics' Research & Development history spans 16 years, with the latest figure at $23.7 million for Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 21.36% year-over-year to $23.7 million, compared with a TTM value of $135.8 million through Dec 2025, up 24.21%, and an annual FY2025 reading of $135.8 million, up 24.21% over the prior year.
- Research & Development for Q4 2025 was $23.7 million at Amicus Therapeutics, up from $23.4 million in the prior quarter.
- The five-year high for Research & Development was $85.6 million in Q4 2021, with the low at $23.4 million in Q3 2025.
- Average Research & Development over 5 years is $47.3 million, with a median of $41.1 million recorded in 2023.
- Year-over-year, Research & Development tumbled 55.12% in 2023 and then surged 146.52% in 2025.
- Tracing FOLD's Research & Development over 5 years: stood at $85.6 million in 2021, then dropped by 25.38% to $63.9 million in 2022, then crashed by 45.16% to $35.0 million in 2023, then dropped by 13.81% to $30.2 million in 2024, then dropped by 21.36% to $23.7 million in 2025.
- Per Business Quant, the three most recent readings for FOLD's Research & Development are $23.7 million (Q4 2025), $23.4 million (Q3 2025), and $60.8 million (Q2 2025).